[1] Crabb D W, Im G Y, Szabo G, et al. Diagnosis and Treatment of Alcohol-Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases[J]. Hepatology, 2020, 71(1): 306-333.
[2] Åberg F, Jiang Z G, Cortez-Pinto H, et al. Alcohol-associated liver disease-Global epidemiology[J]. Hepatology, 2024, 80(6): 1307-1322.
[3] Jophlin L L, Singal A K, Bataller R, et al. ACG Clinical Guideline: Alcohol-Associated Liver Disease[J]. Am J Gastroenterol, 2024, 119(1): 30-54.
[4] Terrault N A, Francoz C, Berenguer M, et al. Liver Transplantation 2023: Status Report, Current and Future Challenges[J]. Clin Gastroenterol Hepatol, 2023, 21(8): 2150-2166.
[5] Whitfield J B, Masson S, Liangpunsakul S, et al. Obesity, Diabetes, Coffee, Tea, and Cannabis Use Alter Risk for Alcohol-Related Cirrhosis in 2 Large Cohorts of High-Risk Drinkers[J]. Am J Gastroenterol, 2021, 116(1): 106-115.
[6] Rinella M E, Lazarus J V, Ratziu V, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature[J]. Hepatology, 2023, 78(6): 1966-1986.
[7] Amonker S, Houshmand A, Hinkson A, et al. Prevalence of alcohol-associated liver disease: a systematic review and meta-analysis[J]. Hepatol Commun, 2023, 7(5): e0133.
[8] Hagström H, Thiele M, Roelstraete B, et al. Mortality in biopsy-proven alcohol-related liver disease: a population-based nationwide cohort study of 3453 patients[J]. Gut, 2021, 70(1): 170-179.
[9] Wester A, Shang Y, Stål P, et al. Time trends in mortality and life expectancy in 22,658 patients hospitalized with alcohol-associated cirrhosis: A nationwide cohort study[J]. Hepatol Commun, 2023, 7(10): e0279.
[10] Kann A E, Jepsen P, Madsen L G, et al. Cause-specific mortality in patients with alcohol-related liver disease in Denmark: a population-based study[J]. Lancet Gastroenterol Hepatol, 2023, 8(11): 1028-1034.
[11] Abeysekera K W M, Fernandes G S, Hammerton G, et al. Prevalence of steatosis and fibrosis in young adults in the UK: a population-based study[J]. Lancet Gastroenterol Hepatol, 2020, 5(3): 295-305.
[12] Singal A K, Arora S, Wong R J, et al. Increasing Burden of Acute-On-Chronic Liver Failure Among Alcohol-Associated Liver Disease in the Young Population in the United States[J]. Am J Gastroenterol, 2020, 115(1): 88-95.
[13] Jepsen P, Younossi Z M. The global burden of cirrhosis: A review of disability-adjusted life-years lost and unmet needs[J]. J Hepatol, 2021, 1(S1): S3-S13.
[14] Huang D Q, Singal A G, Kono Y, et al. Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer[J]. Cell Metab, 2022, 34(7): 969-977.
[15] Pinheiro P S, Jones P D, Medina H, et al. Incidence of Etiology-specific Hepatocellular Carcinoma: Diverging Trends and Significant Heterogeneity by Race and Ethnicity[J]. Clin Gastroenterol Hepatol, 2024, 22(3): 562-571.
[16] Global Burden of Disease Liver Cancer Collaboration, Akinyemiju T, Abera S, et al. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level: Results From the Global Burden of Disease Study 2015[J]. JAMA Oncol, 2017, 3(12): 1683-1691.
[17] Gaurnizo-Ortiz M, Nephew L D, Vilar-Gomez E, et al. Clinical characteristics and prognosis of hospitalized patients with moderate alcohol-associated hepatitis[J]. Liver Int, 2024, 44(1): 241-249.
[18] Thompson J A, Martinson N, Martinson M. Mortality and costs associated with alcoholic hepatitis: A claims analysis of a commercially insured population[J]. Alcohol, 2018, 71: 57-63.
[19] Singal A K, Leggio L, DiMartini A. Alcohol use disorder in alcohol-associated liver disease: Two sides of the same coin[J]. Liver Transpl, 2024, 30(2): 200-212.
[20] Monnig M A, Treloar Padovano H, Monti P M. Alcohol-associated liver disease and behavioral and medical cofactors: unmet needs and opportunities[J]. Front Public Health, 2024, 12: 1322460. |
